紫杉烷类与胺碘酮相互作用致严重毒性
一例77岁HER2阳性乳腺癌患者在接受紫杉醇和曲妥珠单抗辅助治疗时,因合用胺碘酮出现严重皮肤和黏膜毒性,怀疑紫杉烷清除率下降。药代动力学采样证实多西他赛血浆浓度异常升高,个体清除率下降79%,AUC增加约5倍。胺碘酮抑制CYP2C8、CYP3A4和P-gp,但说明书未提及该相互作用。
要点
- 胺碘酮可抑制CYP2C8、CYP3A4和P-gp,增加紫杉烷暴露。
- 合用胺碘酮的患者使用紫杉烷时应警惕严重毒性。
- 说明书未记载该相互作用,老年患者尤其需注意。
研究设计与样本
- 病例报告:一例77岁女性HER2阳性乳腺浸润性导管癌患者,术后接受紫杉醇和曲妥珠单抗辅助治疗,同时服用胺碘酮。
主要发现
- 患者出现严重皮肤和黏膜毒性,与紫杉烷治疗存在强时间关联,怀疑紫杉烷清除率意外降低。
- 多西他赛给药后第9天和第10天血浆浓度分别为4.73和4.09 ng/ml。
- 个体(贝叶斯最大后验)清除率估计值降至9.15 L/h,下降79%,对应AUC增加约5倍。
- 末次给药后20和21天的样本中仍可检测到紫杉醇。
临床怎么用
- 临床医生应知晓胺碘酮与紫杉烷类的相互作用,尤其是老年患者可能因心脏合并症已在使用胺碘酮。
- 对合用胺碘酮的患者使用紫杉烷时,需警惕严重皮肤和黏膜毒性,必要时进行药代动力学监测或调整治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ADVERSE EVENT: A drug interaction leading to severe skin and mucosal toxicity. DRUGS IMPLICATED: Paclitaxel, docetaxel and amiodarone. THE PATIENT: A 77-year-old woman with a history of hypertension, hyperlipidemia, and palpitations, managed with amiodarone, was treated for HER2-positive invasive ductal breast cancer with paclitaxel and trastuzumab as an adjunct to surgery. EVIDENCE THAT LINKS THE DRUG TO THE EVENT: There was a strong temporal relationship between the taxane therapy and the development of severe skin and mucosal toxicity due to an unexpected reduction in taxane clearance. MANAGEMENT: Initially, conversion of paclitaxel to docetaxel, then cessation of docetaxel, symptomatic treatment, rehydration and placement of a nasogastric tube. MECHANISM: Increased exposure to paclitaxel and subsequently docetaxel due to interaction with amiodarone was suspected and confirmed on pharmacokinetic sampling. Analysis of two blood samples taken 9 and 10 days after docetaxel revealed plasma levels of 4.73 and 4.09 ng ml-1 , respectively, leading to a 79% decreased individual (Bayesian maximum a posteriori) clearance estimate of 9.15 l h-1 , corresponding to an estimated fivefold increase in AUC. Paclitaxel was also present in these samples (20 and 21 days after the last administration). IMPLICATIONS FOR THERAPY: Amiodarone inhibits cytochrome P450 (CYP) isoforms 2C8 and 3A4 as well as P-glycoprotein (P-gp) for which taxanes are substrates. However, interactions with amiodarone are not specified in the prescribing information. Clinicians should be aware of this interaction, particularly in an ageing population, where more patients requiring taxanes may already be receiving amiodarone for a comorbid cardiac condition.
引用
- Hammann F, Gotta V, Conen K, et al. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol. 2016. PMID: 27868228. doi:10.1111/bcp.13155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。